Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.30 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29398807 | 0.71 | CA12 (0.45) | CA12CA1CA2CA9CA14 | |
| SCHEMBL88782 | 0.67 | CA9 (0.41) | EGFRERBB2CA12CA1CA2 | |
| SCHEMBL21157145 | 0.64 | GPR3 (0.44) | EGFRERBB2 | |
| SCHEMBL11256812 | 0.60 | CA12 (0.35) | CA12CA1CA2CA9 | |
| SCHEMBL19252612 | 0.60 | CA2 (0.32) | CA2CA9 | |
| SCHEMBL21157146 | 0.59 | GPR3 (0.44) | EGFRERBB2 | |
| SCHEMBL8623987 | 0.59 | CA12 (0.40) | EGFRERBB2CA12CA1CA2 | |
| SCHEMBL89122 | 0.58 | CA1 (0.41) | CA12CA1CA2CA9 | |
| SCHEMBL89180 | 0.58 | EGFR (0.33) | EGFRERBB2CA12CA1CA2 | |
| SCHEMBL11714809 | 0.57 | NQO2 (0.35) | CA12CA1CA2CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2563790-B1 | A PROCESS OF A QUATERNARY AMMONIUM SALT | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2016-09-14 | — | — | EP | disclosed |
| US-9309255-B2 | Process of a quaternary ammonium salt | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-04-12 | — | — | US | disclosed |
| US-20150087830-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT | SUMITOMO DAINIPPON PHARMA CO., LTD | 2015-03-26 | — | — | US | disclosed |
| US-8933229-B2 | 8-azabicyclo[3.2.1]octane-8-carboxamide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-01-13 | — | — | US | disclosed |
| US-8921551-B2 | Process of a quaternary ammonium salt | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-12-30 | — | — | US | disclosed |
| US-20140256939-A1 | PROCESS OF PREPARING A QUATERNARY AMMONIUM SALT USING PHOSPHATE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-09-11 | — | — | US | disclosed |
| US-20140256939-A1 | PROCESS OF PREPARING A QUATERNARY AMMONIUM SALT USING PHOSPHATE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-09-11 | — | — | US | disclosed |
| US-20140031548-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT USING PHOSPHATE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| US-8586737-B2 | Process of a quaternary ammonium salt using phosphate | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-11-19 | — | — | US | disclosed |
| US-8541585-B2 | N-acyl cyclic amine derivative or pharmaceutically acceptable salt thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-09-24 | — | — | US | disclosed |
| US-20110263560-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-10-27 | — | — | US | disclosed |
| WO-2011111875-A1 | N-ACYL CYCLIC AMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | WO | disclosed |
| US-20100160305-A1 | 3, 4, 5 - Substituted Piperidine Compounds | NOVARTIS AG (CH) | 2010-06-24 | — | — | US | disclosed |
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | BREITENSTEIN WERNER | 2010-04-08 | — | — | US | disclosed |
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20090312304-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
| US-20090281161-A1 | Organic Compounds | MAIBAUM JUERGEN KLAUS | 2009-11-12 | — | — | US | disclosed |
| US-20090270417-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-10-29 | — | — | US | disclosed |
| US-20090247577-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | ROGEL OLIVIER | 2009-10-01 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087830-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT | KAT5, ATP1B2, QARS1 | EGFR 4241/4885ERBB2 4580/4885CA12 1011/4885 |
| US-20140031548-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT USING PHOSPHATE | PHPT1, SLC34A2, SLC34A3 | EGFR 4266/4885ERBB2 4672/4885CA12 883/4885 |
| US-20090247577-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | BACE1, BACE2, APP | EGFR 3427/4885ERBB2 1626/4885CA12 4352/4885 |
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | REN, ACE, PEPD | EGFR 4581/4885ERBB2 3920/4885CA12 3286/4885 |
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | REN, PAH, ACE | EGFR 4662/4885ERBB2 3892/4885CA12 2520/4885 |
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | EGFR 3938/4885ERBB2 3187/4885CA12 2906/4885 |
| US-20090281161-A1 | Organic Compounds | REN, ACE, OTC | EGFR 4506/4885ERBB2 3143/4885CA12 1609/4885 |
| US-20090270417-A1 | Organic Compounds | REN, ACE, OTC | EGFR 4506/4885ERBB2 3143/4885CA12 1609/4885 |
| US-20110263560-A1 | Organic Compounds | REN, ACE, OTC | EGFR 4547/4885ERBB2 3764/4885CA12 2345/4885 |
| US-20090312304-A1 | ORGANIC COMPOUNDS | REN, ACE, PIGO | EGFR 4472/4885ERBB2 3766/4885CA12 2337/4885 |
| US-20100160305-A1 | 3, 4, 5 - Substituted Piperidine Compounds | REN, ACE, PIGO | EGFR 4205/4885ERBB2 3297/4885CA12 3666/4885 |
| US-20140256939-A1 | PROCESS OF PREPARING A QUATERNARY AMMONIUM SALT USING PHOSPHATE | AGPS, SLC34A3, SLC34A1 | EGFR 4086/4885ERBB2 4655/4885CA12 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.